Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit Metastasis

Satellitosis/in-transit metastasis (S-ITM) has prognostic value in melanoma and Merkel cell carcinoma, but is not incorporated into cutaneous squamous cell carcinoma (cSCC) staging. From our IRB-approved registry, patients with high-risk cSCC, including patients with S-ITM, were identified. Univaria...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2021-01, Vol.41 (1), p.289-295
Main Authors: Smile, Timothy D, Xiong, David X, Varra, Vamsi, Winter, Ian W, Beal, Brandon T, Gastman, Brian R, Geiger, Jessica L, Adelstein, David J, Bergfeld, Wilma F, Piliang, Melissa P, Billings, Steven D, Ko, Jennifer S, Knackstedt, Thomas J, Lucas, Jennifer L, Poblete-Lopez, Christina M, Meine, Jon G, Vij, Alok, Vidimos, Allison T, Koyfman, Shlomo A
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Carcinoma, Squamous Cell - etiology
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Disease Progression
Female
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
Male
Melanoma
Metastases
Metastasis
Middle Aged
Neoplasm Staging
Prognosis
Recurrence
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Squamous cell carcinoma
Survival Analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Satellitosis/in-transit metastasis (S-ITM) has prognostic value in melanoma and Merkel cell carcinoma, but is not incorporated into cutaneous squamous cell carcinoma (cSCC) staging. From our IRB-approved registry, patients with high-risk cSCC, including patients with S-ITM, were identified. Univariate (UVA) and multivariate (MVA) analyses were performed to compare disease progression (DP) and overall survival (OS). Cumulative incidence of DP and OS analyses were performed using Fine-Gray and Kaplan-Meier methods, respectively. A total of 18 S-ITM subjects were compared to 247 high risk subjects including T3N0 (n=143), N1-N3 without extranodal extension (ENE) (n=56), N1-N3 with ENE (n=26) and M1 disease (n=22). Median follow up was 16.5 months. Three-year rates of DP were 22% for T3N0, 42% for S-ITM, 48% for T4 bone invasion, 50% for N1-N3 without extranodal extension (ENE), 53% for N1-N3 with ENE, and 66% for M1. Patients with S-ITM did not experience significantly worse DP compared to those with T3N0 (HR=1.96, 95%CI=0.8-4.9; p=0.14). Cutaneous SCC patients with S-ITM experienced outcomes similar to locally advanced non-metastatic cSCC patients. Larger studies are needed to guide incorporation into staging systems.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14775